From June 1997 to May 1998, among the 7678 people with type 2 diabetes, 901 (11.7%) were being treated with insulin (Table 2), 2823 (36.8%) were being treated with sulfonylureas (group b), and 3954 (51.5%) were being treated with non-insulin secretagogues alone (group a). This evidence concerns the gene INS and type 2 diabetes mellitus.